CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, has signed a contract for distribution of its Vergenix Flowable Gel product covering Belarus, Kazakhstan, Georgia, Azerbaijan, Armenia and Uzbekistan, it was reported on Monday.
The firm stated that it has received its first order for a fee running into hundreds of thousands of US dollars. According to the terms of the deal, CollPlant will deliver a part of the order immediately and the remainder over the next six months, with the contract covering a five-year period.
The product is based on the firm's rhCollagen technology aimed at treating acute and chronic hard-to-heal wounds including diabetic ulcers, pressure sores, surgical cuts and trauma wounds.
Novo Nordisk to streamline operations and reinvest in diabetes and obesity growth
NICE endorses AOTI's TWO2 therapy for diabetic foot ulcers
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
OptiBiotix signs distribution deal with major weight management company
GoodRx partners with Novo Nordisk to offer Ozempic and Wegovy at USD499 per month
Ocular Therapeutix secures FDA special protocol assessment for AXPAXLI NPDR trial
MetaVia collaborates with Syntekabio to explore AI-driven indications for DA-1241
Ascletis completes participant dosing in US obesity clinical study
BioLab Holdings' amnion grafts enter multicentre clinical trial